FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/논문
연구 도서관으로 돌아가기
PubMedRandomized Controlled Trial인간 피험자

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

Rubino Domenica M, Greenway Frank L, Khalid Usman, O'Neil Patrick M, Rosenstock Julio, Sørrig Rasmus, Wadden Thomas A, Wizert Alicja, Garvey W Timothy
JAMA2022DOI: 10.1001/jama.2021.23619
semaglutideliraglutide

품질 점수

7/10

참조 문헌

0

피험자

인간

Peptide Contacts 분석

Study Design

As a randomized controlled trial, this study represents the highest tier of clinical evidence. The randomized design controls for confounding variables, making causal inferences more robust than observational studies.

Our Assessment

Quality Assessment: 7/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

The results for semaglutide, liraglutide are encouraging. Critically, these findings come from human data — not animal models or in-vitro work — which makes them directly relevant to clinical applications. The study design adds significant weight to these conclusions.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. Specifically: the follow-up period was relatively short — long-term efficacy and safety remain open questions. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: This is high-quality human evidence for semaglutide, liraglutide. If you're tracking the research landscape for these compounds, this paper deserves a close read.

주요 발견

The study found that once-weekly subcutaneous semaglutide resulted in significantly greater weight loss compared to daily liraglutide among adults with overweight or obesity without diabetes, after a 68-week period.

제한 사항

The study had a relatively short follow-up period and did not include participants with diabetes. The open-label design may have influenced participant behavior and reporting of outcomes.

이 연구를 어떻게 해석해야 하는지

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Examine the primary endpoint — did the study measure what actually matters clinically, or a proxy marker?

4

Statistical significance (p < 0.05) does not always mean clinical significance. Look at the actual effect size.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Peptide Contacts 분석

Highlighting the comparative effectiveness and patient outcomes between once-weekly semaglutide and daily liraglutide for weight management in non-diabetic obese patients.

semaglutideliraglutide

Weekly Semaglutide Outperforms Daily Liraglutide in Weight Loss for Non-Diabetic Obese Adults

Published: May 17, 2026 | Source: JAMA (2022) | Category: semaglutide, liraglutide

Overview

A recent study published in the Journal of the American Medical Association (JAMA) has shown that once-weekly subcutaneous semaglutide leads to significantly greater weight loss compared to daily liraglutide among adults with overweight or obesity but without diabetes. This finding is crucial for individuals seeking effective peptide therapies for weight management.

Study Background

Previous research had established the efficacy of both glucagon-like peptide-1 (GLP-1) analogues, semaglutide and liraglutide, in managing body weight. However, direct comparisons between these two treatments were lacking. The STEP 8 trial aimed to address this gap by comparing the effectiveness and safety profiles of once-weekly subcutaneous semaglutide at 2.4 mg versus daily liraglutide at 3.0 mg for weight management in non-diabetic obese adults.

What the Research Found

The study, conducted over a period of 68 weeks, involved 338 participants who were randomized to receive either once-weekly semaglutide (126 participants), daily liraglutide (127 participants), or placebo. The primary outcome was percentage change in body weight from baseline. By the end of the study period, those receiving semaglutide experienced an average weight loss of 15.8%, compared to 6.4% for those on liraglutide, representing a significant difference of -9.4 percentage points (p < 0.001). Additionally, more participants in the semaglutide group achieved clinically meaningful weight loss milestones: 72% reached at least 10% weight loss, compared to 35% for liraglutide.

What This Means for Peptide Users

For individuals looking to manage their body weight through peptide therapy and who do not have diabetes, the results suggest that semaglutide may be a more effective option than daily liraglutide. The once-weekly dosing of semaglutide could also offer greater convenience compared to the daily regimen required for liraglutide.

Limitations and Caveats

While the study provides compelling evidence, it is important to note several limitations. First, the trial had a relatively short follow-up period of 68 weeks, which may not fully capture long-term outcomes or side effects. Second, the study excluded participants with diabetes, limiting its applicability to this population. Lastly, the open-label design might have influenced participant behavior and reporting of adverse events.

How This Compares to Previous Research

Previous studies had shown that both semaglutide and liraglutide were effective in promoting weight loss; however, direct comparisons between these two treatments were limited. The STEP 8 trial provides a definitive comparison, highlighting the superior efficacy of semaglutide for non-diabetic obese adults.

Our Analysis

PeptideVault's analysis indicates that this study offers valuable insights into the comparative effectiveness of once-weekly semaglutide versus daily liraglutide for weight management in non-diabetic individuals. The significant difference in weight loss outcomes supports the potential benefits of semaglutide as a preferred treatment option. However, further research is needed to confirm these findings over longer periods and across diverse populations.

Key Takeaways

  • Greater Efficacy: Once-weekly semaglutide resulted in significantly more weight loss compared to daily liraglutide.
  • Convenience Factor: The once-weekly dosing of semaglutide offers a practical advantage for patients.
  • Further Research Needed: Long-term studies and investigations into the effects on diabetic populations are warranted.

Original Source

Citation: Rubino Domenica M, Greenway Frank L, Khalid Usman et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.. JAMA. DOI: 10.1001/jama.2021.23619

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

편집자의 주석

Peptide Contacts 연구 팀은 복잡한 발견을 피테이드 커뮤니티에게 이해하기 쉬운 언어로 작성했습니다. 항상 원문의 전체 방법론과 데이터를 참조하십시오. semaglutide에 대해 더 알아보기 연구 가이드.

참조 문헌

Rubino Domenica M, Greenway Frank L, Khalid Usman et al.. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.. JAMA. https://doi.org/10.1001/jama.2021.23619

PubMed에서 전체 텍스트 확인하기

관련 논문

더 알아보기

이 내용은 교차 검토된 연구를 기반으로 교육 목적용으로 생성되었습니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 피테이드 기반 치료법을 사용하기 전에 항상 자격 있는 의료 전문가와 상담하십시오.